AQIA (Aquiva Group) Notes Receivable: $0.00 Mil (As of Sep. 2008)


What is Aquiva Group Notes Receivable?

Aquiva Group AQIA Notes Receivable is $0.00 Mil as of Sep. 2008.

Aquiva Group's Notes Receivable for the quarter that ended in Sep. 2008 was $0.00 Mil.

Aquiva Group Notes Receivable Historical Data

* Premium members only.

The historical data trend for Aquiva Group's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aquiva Group Notes Receivable Chart

Aquiva Group Annual Data
Trend Mar06 Mar07 Mar08
Notes Receivable
0.00 0.00 0.00

Aquiva Group Quarterly Data
Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Aquiva Group Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
Aquiva Group (AQIA) has a Notes Receivable of $0.00 Mil as of Sep. 2008. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Aquiva Group and its competitors.
Is Aquiva Group's Notes Receivable too high?
Aquiva Group's current Notes Receivable is $0.00 Mil.
How does Aquiva Group's Notes Receivable compare to LOGQ and MUSS?
Aquiva Group's Notes Receivable of $0.00 Mil can be compared against companies in the Software industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Software company?
A good Notes Receivable depends on the Software industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Aquiva Group and its competitors. Aquiva Group's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aquiva Group stock overvalued right now?
Aquiva Group (AQIA) has a current Notes Receivable of $0.00 Mil. The current Notes Receivable is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Aquiva Group (AQIA), the current Notes Receivable is $0.00 Mil as of Sep. 2008. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aquiva Group Business Description

Address No. 3 Bethesda Metro Center, Suite 700, Bethesda, MD, USA, 20814
Aquiva Group Inc is focused on commercializing materials science technologies in both existing and emerging markets. It has licensed a novel HiPNATM (Hydrogel with InterPenetrating Network Anchor) technology, branded as AquiFormTM, which is a versatile material with key properties, making it an attractive platform for various applications. These applications include transdermal patches that release active ingredients for skin care, nutraceuticals, and other healthcare and cosmetics markets. The company operates across three segments: Consumer Health, Wellness, & Cosmetics; Medical Device; and Therapeutics & Transdermal Drug-Delivery Systems (TDS). Additionally, it is building on an established partnership network and capabilities in contract development to expand its services to new areas.